Your browser is no longer supported. Please, upgrade your browser.
Settings
MGTA Magenta Therapeutics, Inc. daily Stock Chart
MGTA [NASD]
Magenta Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.56 Insider Own14.33% Shs Outstand33.15M Perf Week5.87%
Market Cap567.86M Forward P/E- EPS next Y-2.38 Insider Trans- Shs Float27.03M Perf Month10.44%
Income-61.30M PEG- EPS next Q-0.54 Inst Own72.80% Short Float5.82% Perf Quarter97.58%
Sales- P/S- EPS this Y-203.20% Inst Trans4.04% Short Ratio7.01 Perf Half Y120.46%
Book/sh4.01 P/B4.27 EPS next Y-7.70% ROA-37.20% Target Price20.00 Perf Year-
Cash/sh3.84 P/C4.46 EPS next 5Y- ROE-40.10% 52W Range5.31 - 21.00 Perf YTD200.53%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-18.43% Beta-
Dividend %- Quick Ratio17.10 Sales past 5Y- Gross Margin- 52W Low222.60% ATR1.16
Employees62 Current Ratio17.10 Sales Q/Q- Oper. Margin- RSI (14)55.49 Volatility5.55% 8.31%
OptionableNo Debt/Eq0.00 EPS Q/Q84.40% Profit Margin- Rel Volume0.40 Prev Close17.24
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 Payout- Avg Volume224.43K Price17.13
Recom2.00 SMA208.31% SMA505.67% SMA20049.95% Volume89,946 Change-0.64%
Mar-25-19Downgrade Goldman Buy → Neutral $17 → $16
Mar-15-19Initiated Raymond James Outperform
Jul-16-18Initiated Wedbush Outperform $22
Jul-16-18Initiated JP Morgan Overweight $18
Jul-16-18Initiated Goldman Buy $18
May-09-19 08:00AM  Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights Business Wire
07:30AM  Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting Business Wire
May-06-19 04:05PM  Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-01-19 08:11PM  Magenta Therapeutics Announces Pricing of Public Offering Business Wire
Apr-29-19 04:32PM  Magenta Therapeutics Launches Proposed Public Offering Business Wire
08:00AM  Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy Business Wire
Apr-24-19 08:30AM  Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate Business Wire +5.54%
Apr-07-19 06:00PM  3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Mar-20-19 12:07PM  Raymond James Thinks Magenta Still Has Upside GuruFocus.com
Mar-19-19 07:30AM  Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights Business Wire
Mar-15-19 01:32PM  How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares? Simply Wall St. +26.19%
Mar-06-19 04:05PM  Magenta Therapeutics to Present at Investor Conferences in March Business Wire
Feb-25-19 08:15AM  Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate Business Wire +12.03%
08:15AM  Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting Business Wire
Feb-21-19 08:00AM  Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant Business Wire -5.66%
Feb-07-19 08:30AM  Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference Business Wire
Jan-02-19 08:30AM  Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 Business Wire +5.26%
Dec-02-18 09:00PM  Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit Business Wire
09:00PM  Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders Business Wire
Dec-01-18 12:30PM  Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate Business Wire
Nov-26-18 08:30AM  Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH Business Wire
Nov-19-18 08:00AM  Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer Business Wire
Nov-08-18 08:00AM  Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results Business Wire
Nov-01-18 09:00AM  Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs Business Wire -5.82%
Sep-24-18 08:30AM  Magenta Therapeutics Added to Russell 2000 and 3000 Indexes Business Wire +5.92%
Aug-09-18 04:05PM  Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results Business Wire
Aug-08-18 04:05PM  Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference Business Wire
Jul-25-18 07:40AM  Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-16-18 12:33PM  Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful Benzinga
Jul-03-18 06:23AM  Goodwin dominates this years record batch of Mass. biotech IPOs American City Business Journals
Jun-25-18 04:05PM  Magenta Therapeutics Announces Closing of Initial Public Offering Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 10:01PM  [$$] Eidos Therapeutics Goes Public, Joining Biotech IPO Flurry The Wall Street Journal
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
Jun-18-18 01:36PM  Don't Fear This Burst of Biotech IPOs Bloomberg
Jun-17-18 04:22PM  The IPO Outlook For The Week Of June 18: Pharma, Pharma And More Pharma Benzinga
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.